The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons
Open accessAbstract
Although the mechanisms underlying the loss of neurons in Parkinson's disease are not well understood, impaired mitochondrial function and pathological protein aggregation are suspected as playing a major role. Why DA (dopamine) neurons and a select small subset of brain nuclei are particularly vulnerable to such ubiquitous cellular dysfunctions is presently one of the key unanswered questions in Parkinson's disease research. One intriguing hypothesis is that their heightened vulnerability is a consequence of their elevated bioenergetic requirements. Here, we show for the first time that vulnerable nigral DA neurons differ from less vulnerable DA neurons such as those of the VTA (ventral tegmental area) by having a higher basal rate of mitochondrial OXPHOS (oxidative phosphorylation), a smaller reserve capacity, a higher density of axonal mitochondria, an elevated level of basal oxidative stress, and a considerably more complex axonal arborization. Furthermore, we demonstrate that reducing axonal arborization by acting on axon guidance pathways with Semaphorin 7A reduces in parallel the basal rate of mitochondrial OXPHOS and the vulnerability of nigral DA neurons to the neurotoxic agents MPP(+) (1-methyl-4-phenylpyridinium) and rotenone. Blocking L-type calcium channels with isradipine was protective against MPP(+) but not rotenone. Our data provide the most direct demonstration to date in favor of the hypothesis that the heightened vulnerability of nigral DA neurons in Parkinson's disease is directly due to their particular bioenergetic and morphological characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mitochondria, Oxidants, and Aging
Balaban, R. S., Nemoto, S., & Finkel, T. (2005) · Cell · doi:10.1016/j.cell.2005.02.001 · Cited by 4,388
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 1×
“We used qPCR to examine the level of expression of PGC-1a (peroxisome proliferator-activated receptor g coactivator), a well-known regulator of mitochondrial function and biogenesis [15].”
MethodSynaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · cited 1×
“However, our results do not exclude that, in addition, other sources of ROS such as those arising from the oxidative metabolism of DA itself [32] could also play a role.”
ResultZong, H., Ren, J. M., Young, L. H., Pypaert, M., Mu, J., Birnbaum, M. J., & Shulman, G. I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252625599 · Cited by 1,036
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 857
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
Lenaz, G. (2001) · IUBMB Life · doi:10.1080/15216540152845957 · Cited by 585
Semaphorin 7A promotes axon outgrowth through integrins and MAPKs
Jeroen Pasterkamp, R., Peschon, J. J., Spriggs, M. K., & Kolodkin, A. L. (2003) · Nature · doi:10.1038/nature01790 · Cited by 515
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Robust Pacemaking in Substantia Nigra Dopaminergic Neurons
Guzman, J. N., Sánchez-Padilla, J., Chan, C. S., & Surmeier, D. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2519-09.2009 · Cited by 411
Pissadaki, E. K., & Bolam, J. P. (2013) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2013.00013 · Cited by 348
Huisman, E., Uylings, H. B. M., & Hoogland, P. V. (2004) · Movement Disorders · doi:10.1002/mds.10713 · Cited by 313
Mitochondrial Biology and Parkinson's Disease
Perier, C., & Vila, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009332 · Cited by 306
Redox imbalance in Parkinson's disease
Chinta, S. J., & Andersen, J. K. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.02.005 · Cited by 302
Mudò, G., Mäkelä, J., Liberto, V. D., Tselykh, T. V., Olivieri, M., Piepponen, P., Eriksson, O., Mälkiä, A., Bonomo, A., Kairisalo, M., et al. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0850-z · Cited by 301
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
PGC-1α and PGC-1Β Regulate Mitochondrial Density in Neurons
Wareski, P., Vaarmann, A., Choubey, V., Safiulina, D., Liiv, J., Kuum, M., & Kaasik, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018911 · Cited by 294
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijic, E., Guzman, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 259
Choi, W.-S., Kruse, S. E., Palmiter, R. D., & Xia, Z. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807581105 · Cited by 236
Dryanovski, D. I., Guzman, J. N., Xie, Z., Galteri, D. J., Volpicelli-Daley, L. A., Lee, V. M. Y., Miller, R. J., Schumacker, P. T., & Surmeier, D. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5311-12.2013 · Cited by 212
Dynamics of tyrosine hydroxylase promoter activity during midbrain dopaminergic neuron development
Matsushita, N., Okada, H., Yasoshima, Y., Takahashi, K., Kiuchi, K., & Kobayashi, K. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00972.x · Cited by 211
Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol
Meredith, G. E., Totterdell, S., Potashkin, J. A., & Surmeier, D. J. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.012 · Cited by 193
Selective Vulnerability of Dopaminergic Neurons to Microtubule Depolymerization
Ren, Y., Liu, W., Jiang, H., Jiang, Q., & Feng, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503483200 · Cited by 188
Getting connected in the dopamine system
VANDENHEUVEL, D., & PASTERKAMP, R. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.003 · Cited by 186
Liang, C.-L., Wang, T. T., Luby-Phelps, K., & German, D. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.015 · Cited by 185
Retrograde semaphorin signaling regulates synapse elimination in the developing mouse brain
Uesaka, N., Uchigashima, M., Mikuni, T., Nakazawa, T., Nakao, H., Hirai, H., Aiba, A., Watanabe, M., & Kano, M. (2014) · Science · doi:10.1126/science.1252514 · Cited by 166
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration
Storch, A., Ludolph, A. C., & Schwarz, J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0203-2 · Cited by 151
The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3521 · Cited by 142
The axonal arborization of single nigrostriatal neurons in rats
Gauthier, J., Parent, M., Lévesque, M., & Parent, A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01573-5 · Cited by 140
Self-citationCiron, C., Lengacher, S., Dusonchet, J., Aebischer, P., & Schneider, B. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr618 · Cited by 139
Méndez, J. A. T., Bourque, M.-J., Bo, G. D., Bourdeau, M. L., Danik, M., Williams, S., Lacaille, J., & Trudeau, L. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1331-08.2008 · Cited by 133
Self-citationMitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease
Pacelli, C., Rasmo, D. D., Signorile, A., Grattagliano, I., Tullio, G. D., D’Orazio, A., Nico, B., Comi, G. P., Ronchi, D., Ferranini, E., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.022 · Cited by 124
Self-citationChan, C. S., Gertler, T. S., & Surmeier, D. J. (2010) · Movement Disorders · doi:10.1002/mds.22801 · Cited by 122
Kupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110
Hung, H.-C., & Lee, E. H. Y. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00062-9 · Cited by 108
Pasterkamp, R. J., Kolk, S. M., Hellemons, A. J. C. G. M., & Kolodkin, A. L. (2007) · BMC Developmental Biology · doi:10.1186/1471-213x-7-98 · Cited by 98
Hashimoto, T., Nishi, K., Nagasao, J., Tsuji, S., & Oyanagi, K. (2008) · Brain Research · doi:10.1016/j.brainres.2007.12.033 · Cited by 83
Clark, J., Silvaggi, J. M., Kiselak, T., Zheng, K., Clore, E. L., Dai, Y., Bass, C. E., & Simon, D. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048925 · Cited by 77
Semaphorins 3A, 3C, and 3F in mesencephalic dopaminergic axon pathfinding
Hernández-Montiel, H. L., Tamaríz, E., Sandoval‐Minero, M. T., & Varela‐Echavarría, A. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21503 · Cited by 75
Culture of Postnatal Mesencephalic Dopamine Neurons on an Astrocyte Monolayer
Fasano, C., Thibault, D., & Trudeau, L. (2008) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0321s44 · Cited by 58
Self-citationLuk, K. C., Rymar, V. V., van den Munckhof, P., Nicolau, S., Steriade, C., Bifsha, P., Drouin, J., & Sadikot, A. F. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12160 · Cited by 58
Jongbloets, B. C., Ramakers, G. M. J., & Pasterkamp, R. J. (2013) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.01.002 · Cited by 50
Yu, X., Li, X.-H., Jiang, G., Wang, X., Chang, H. C., Hsu, W. H., & Li, Q. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.062 · Cited by 48
Relationship between axonal collateralization and neuronal degeneration in basal ganglia
Parent, M., & Parent, A. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_14 · Cited by 44
Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41
Cross‐talk between L‐type Ca2+ channels and mitochondria
Viola, H. M., & Hool, L. C. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05277.x · Cited by 34
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand
McWilliams, T. G., Prescott, A. R., Montava-Garriga, L., Ball, G., Singh, F., Barini, E., Muqit, M. M. K., Brooks, S. P., & Ganley, I. G. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.12.008 · Cited by 591
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
Disruption of mitochondrial complex I induces progressive parkinsonism
González-Rodríguez, P., Zampese, E., Stout, K. A., Guzman, J. N., Ilijic, E., Yang, B., Tkatch, T., Stavarache, M. A., Wokosin, D. L., Gao, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04059-0 · Cited by 546
Ge, P., Dawson, V. L., & Dawson, T. M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00367-7 · Cited by 496
Metadata
- Authors
- Pacelli, C., Giguère, N., Bourque, M.-J., Lévesque, M., Slack, R. S., & Trudeau, L.-É.
- Venue
- Current Biology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 25
- Issue
- 18
- Pages
- 2349-2360
- ISSN
- 0960-9822 (ISSN-L)
- OpenAlex
- W1698967089
- Cited by
- 530
- References
- 53
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.